Adenosine Tiphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer

Cancer

Volumn 109, Issue 9, 2007, Pages 1829-1835

  Yong, Wha Moon ^a   Sung, Ho Choi ^b   Yong, Tai Kim ^c   Joo, Hyuk Sohn ^a   Chang, Joon ^a   Se, Kyu Kim ^a   Moo, Suk Park ^a   Kyung, Young Chung ^a   Hyoun, Ju Lee ^b   Kim, Joo Hang ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Isu Abxis Co Ltd   (South Korea)

^c National Health Insurance Corporation   (South Korea)

Author keywords

Adenosine triphosphate; Chemotherapy response assay; Nonsmall cell lung cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMOSENSITIVITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CHOICE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; BIOASSAY; DRUG SCREENING; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTION AND FORECASTING;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SCREENING ASSAYS, ANTITUMOR; ENDPOINT DETERMINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS;

EID: 34247619660     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22601     Document Type: Article

References (27)

1. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355:479-485.
2. Von Hoff DD, Sandbach JF, Clark GM, et al. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst. 1990;82:110-116.
3. Wilbur DW, Camacho ES, Hilliard DA, et al. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br J Cancer. 1992;65:27-32.
4. Shaw GL, Gazdar AF, Phelps R, et al. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996;24: 173-185.
5. Xu JM, Song ST, Tang ZM, et al. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat. 1999;53:77-85.
6. Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs. 1998;9:51-57.
7. Loizzi V, Chan JK, Osann K, et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol. 2003;189:1301-1307.
8. Maenpaa JU, Heinonen E, Hinkka SM, et al. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol. 1995;57: 294-298.
9. Cree IA, Kurbacher CM. Individualizing chemotherapy for solid tumors - is there any alternative? Anticancer Drugs. 1997;8:541-548.
10. Sharma S, Neale MH, Di Nicolantonio F, et al. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer. 2003;3:19-28.
11. Kawamura H, Ikeda K, Takiyama I, et al. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer. 1997;33:960-966.
12. Konecny G, Crohns C, Pegram M, et al. Correlation of drug response with the ATP tumor chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol. 2000;77: 258-263.
13. Koechli OR, Avner BP, Sevin BU, et al. Application of the adenosine triphosphate-cell viability assay in human breast cancer chemosensitivity testing: a report on the first results. J Surg Oncol. 1993;54:119-125.
14. Maehara Y, Anai H, Tamada R, et al. The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol. 1987;23:273-276.
15. Petty RD, Sutherland LA, Hunter EM, et al. Comparison of MTT and ATP-based assays for the measurement of viable cell number. J Biolumin Chemilumin. 1995;10:29-34.
16. Kang SM, Park MS, Chang I, et al. A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Res Treat. 2005;37:223-227.
17. Greene FL, Balch CM, Page DL, et al, editors. AICC Cancer Staging Manual. 6th ed. New York: Springer; 2002:99-103.
18. Schrump DS, Altorki NK, Henschke CL, et al. Non-small cell lung cancer. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:795-798.
19. Kim BS, Ahn YM, Kim I, et al. Clinical utility of adenosine triphosphate-based chemosensitivity response assay (ATP-CRA) in non-small cell lung cancer: preliminary study. Proceedings of the American Society of Clinical Oncology; 2004. Abstract 7259.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
21. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
22. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20: 4285-4291.
23. Schrag D, Garewal HS, Burstein HI, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004;22: 3631-3638.
24. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197:461-463.
25. Selby P, Buick RN, Tannock I. A critical appraisal of the human tumor stem-cell assay. N Engl J Med. 1983:308:129-134.
26. Cree IA, Kurbacher CM, Untch M, et al. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs. 1996;7:630-635.
27. Nakamura R, Saikawa Y, Kubota T, et al. Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy. Anticancer Res. 2006;26:1433-1437.